BD Launches Innovative Central Venous Catheter System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 29 2026
0mins
Source: PRnewswire
Becton Dickinson and Co (BD) has seen its stock price decline by 3.02%, hitting a 52-week low amid mixed market conditions, with the Nasdaq-100 slightly up and the S&P 500 down.
The core catalyst for BD's recent developments is the launch of the CentroVena One™ Insertion System, the first all-in-one central venous catheter device designed to enhance patient safety and streamline procedures for clinicians. This product innovation is expected to significantly impact BD's market presence in the acute care sector, demonstrating the company's commitment to improving healthcare delivery.
The introduction of the CentroVena One™ not only expands BD's vascular access portfolio but also reflects its strategy to reduce complications associated with vascular access, potentially leading to improved clinical outcomes and economic benefits for healthcare providers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 148.410
Low
157.00
Averages
192.64
High
232.00
Current: 148.410
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Blue Chip Stock Investment Strategies
- Microsoft's Growth Potential: Microsoft (MSFT) boasts a market cap exceeding $3 trillion, with an average annual growth of 21% over the past 15 years; despite a recent 12% drop, its forward P/E ratio of 22 is attractive compared to the five-year average of 30.
- Healthcare Sector Leader: Becton, Dickinson (BD) leads in medical devices, producing over 34 billion devices annually, with a 2025 report indicating 125 new product launches and a dividend yield of 2.8%, ensuring stable revenue streams.
- Clorox's Dividend Appeal: Clorox (CLX) has seen a 25% stock price decline, resulting in a forward P/E ratio of 13, below the five-year average of 24, and a dividend yield of 5.1%, making it appealing for long-term investors.
- Market Challenges and Responses: Despite facing cost pressures from rising oil prices, Clorox's management reported positive performance in consumer categories, indicating brand resilience and sustained market demand.
See More
Microsoft Shares Undervalued; Blue Chip Investment Opportunities
- Microsoft's Stock Appeal: With a market value exceeding $3 trillion and an average annual growth rate of 21% over the past 15 years, Microsoft's recent 12% drop has lowered its forward P/E ratio to 22, significantly below the five-year average of 30, indicating strong investment potential.
- BD's Steady Growth: Becton, Dickinson produces over 34 billion medical devices annually, and its 2025 report highlights the launch of over 125 new products and an additional $1.3 billion in revenue from more than 20 acquisitions, showcasing its robust innovation in the medical supply sector.
- Clorox's Dividend Appeal: Clorox boasts a dividend yield of 5.1% and has increased its payout for 48 consecutive years; despite a more than 25% drop in stock price over the past year, its forward P/E ratio stands at 13, well below the five-year average of 24, suggesting investment value.
- Market Environment Impact: Facing rising oil prices that could cost over $20 million in quarterly gross profit, Clorox is working on efficiency improvements, with the CEO noting that consumer spending on brands remains strong, indicating resilience in challenging market conditions.
See More
BD Launches New Laser System to Enhance Urology Efficiency
- Technological Innovation: BD has launched the Elyra™ Thulium Fiber Laser System, designed to enhance efficiency and versatility for urology teams in kidney stone management and soft tissue procedures, significantly improving clinical operations by supporting efficient stone dusting and reducing stone migration.
- User Experience Enhancement: The system features an intuitive user interface, customizable presets, quick startup capabilities, and an optional wireless footswitch, which help streamline workflows in stone lithotripsy and soft tissue procedures, thereby boosting clinicians' confidence during operations.
- Positive Clinical Feedback: BD recently completed its first clinical cases using the Elyra™ Plus TFL System at a leading medical center, receiving positive feedback from urologists and laser technicians who appreciated the system's safety features and ease of use.
- Market Expansion: The Elyra™ and Elyra™ Plus TFL Systems are now available in the United States, as BD continues to expand its urologic stone management portfolio by integrating comprehensive solutions that support providers in optimizing performance and preparing for the future of urologic care.
See More
BD Appoints New Executive Vice President
- Leadership Change: BD has announced the appointment of Peter Menziuso as Executive Vice President and President of BD Interventional effective June 1, aiming to leverage his over 30 years of global healthcare leadership experience to drive sustained growth.
- Performance-Driven Background: Menziuso previously served as Company Group Chairman at Johnson & Johnson Vision, overseeing a $5 billion global business across commercial operations, R&D, and supply chain, showcasing his exceptional ability to drive performance.
- Strategic Leadership Advantage: With a customer-centric approach, Menziuso excels in building high-performing teams and translating strategy into sustained performance, which is expected to bring new growth momentum to BD Interventional and further solidify its market leadership.
- Company Vision and Mission: As one of the world's largest pure-play medical technology companies, BD is committed to advancing healthcare through innovation, and Menziuso's addition is anticipated to enhance clinical operations and improve patient care quality, strengthening the company's influence in the global healthcare market.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Becton Dickinson Exceeds Q2 Estimates with $4.71B Revenue
- Performance Beat: Becton Dickinson reported Q2 revenue of $4.71 billion, surpassing market expectations, indicating strong demand and solid market share in the medical device sector.
- Earnings Outlook Raised: The company raised its 2026 earnings outlook, reflecting confidence in future growth, which is expected to further boost investor confidence and stock performance.
- Executive Change: The appointment of new CFO Vitor Roque signifies a major shift in financial management and strategic execution, potentially impacting future financial decisions and investment directions.
- Positive Market Reaction: Following the earnings beat and raised outlook, the market reacted positively to Becton Dickinson, likely attracting more investor attention and enhancing the company's competitiveness in the healthcare industry.
See More
Analysis of Blue Chip Stock Investment Strategies
- Microsoft's Growth Potential: Microsoft (MSFT) boasts a market cap exceeding $3 trillion, with an average annual growth of 21% over the past 15 years; despite a recent 12% drop, its forward P/E ratio of 22 is attractive compared to the five-year average of 30.
- Healthcare Sector Leader: Becton, Dickinson (BD) leads in medical devices, producing over 34 billion devices annually, with a 2025 report indicating 125 new product launches and a dividend yield of 2.8%, ensuring stable revenue streams.
- Clorox's Dividend Appeal: Clorox (CLX) has seen a 25% stock price decline, resulting in a forward P/E ratio of 13, below the five-year average of 24, and a dividend yield of 5.1%, making it appealing for long-term investors.
- Market Challenges and Responses: Despite facing cost pressures from rising oil prices, Clorox's management reported positive performance in consumer categories, indicating brand resilience and sustained market demand.
See More
Microsoft Shares Undervalued; Blue Chip Investment Opportunities
- Microsoft's Stock Appeal: With a market value exceeding $3 trillion and an average annual growth rate of 21% over the past 15 years, Microsoft's recent 12% drop has lowered its forward P/E ratio to 22, significantly below the five-year average of 30, indicating strong investment potential.
- BD's Steady Growth: Becton, Dickinson produces over 34 billion medical devices annually, and its 2025 report highlights the launch of over 125 new products and an additional $1.3 billion in revenue from more than 20 acquisitions, showcasing its robust innovation in the medical supply sector.
- Clorox's Dividend Appeal: Clorox boasts a dividend yield of 5.1% and has increased its payout for 48 consecutive years; despite a more than 25% drop in stock price over the past year, its forward P/E ratio stands at 13, well below the five-year average of 24, suggesting investment value.
- Market Environment Impact: Facing rising oil prices that could cost over $20 million in quarterly gross profit, Clorox is working on efficiency improvements, with the CEO noting that consumer spending on brands remains strong, indicating resilience in challenging market conditions.
See More
BD Launches New Laser System to Enhance Urology Efficiency
- Technological Innovation: BD has launched the Elyra™ Thulium Fiber Laser System, designed to enhance efficiency and versatility for urology teams in kidney stone management and soft tissue procedures, significantly improving clinical operations by supporting efficient stone dusting and reducing stone migration.
- User Experience Enhancement: The system features an intuitive user interface, customizable presets, quick startup capabilities, and an optional wireless footswitch, which help streamline workflows in stone lithotripsy and soft tissue procedures, thereby boosting clinicians' confidence during operations.
- Positive Clinical Feedback: BD recently completed its first clinical cases using the Elyra™ Plus TFL System at a leading medical center, receiving positive feedback from urologists and laser technicians who appreciated the system's safety features and ease of use.
- Market Expansion: The Elyra™ and Elyra™ Plus TFL Systems are now available in the United States, as BD continues to expand its urologic stone management portfolio by integrating comprehensive solutions that support providers in optimizing performance and preparing for the future of urologic care.
See More
BD Appoints New Executive Vice President
- Leadership Change: BD has announced the appointment of Peter Menziuso as Executive Vice President and President of BD Interventional effective June 1, aiming to leverage his over 30 years of global healthcare leadership experience to drive sustained growth.
- Performance-Driven Background: Menziuso previously served as Company Group Chairman at Johnson & Johnson Vision, overseeing a $5 billion global business across commercial operations, R&D, and supply chain, showcasing his exceptional ability to drive performance.
- Strategic Leadership Advantage: With a customer-centric approach, Menziuso excels in building high-performing teams and translating strategy into sustained performance, which is expected to bring new growth momentum to BD Interventional and further solidify its market leadership.
- Company Vision and Mission: As one of the world's largest pure-play medical technology companies, BD is committed to advancing healthcare through innovation, and Menziuso's addition is anticipated to enhance clinical operations and improve patient care quality, strengthening the company's influence in the global healthcare market.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Becton Dickinson Exceeds Q2 Estimates with $4.71B Revenue
- Performance Beat: Becton Dickinson reported Q2 revenue of $4.71 billion, surpassing market expectations, indicating strong demand and solid market share in the medical device sector.
- Earnings Outlook Raised: The company raised its 2026 earnings outlook, reflecting confidence in future growth, which is expected to further boost investor confidence and stock performance.
- Executive Change: The appointment of new CFO Vitor Roque signifies a major shift in financial management and strategic execution, potentially impacting future financial decisions and investment directions.
- Positive Market Reaction: Following the earnings beat and raised outlook, the market reacted positively to Becton Dickinson, likely attracting more investor attention and enhancing the company's competitiveness in the healthcare industry.
See More
